4 results about "Bacillus infections" patented technology

The application discloses application of elvitegravir in preparation of an inhibitor of mycobacterium tuberculosis or non-tuberculous mycobacteria, and relates to the technical field of biological medicine.The application discloses, for the first time, that elvitegravir has the effect of inhibiting intracellular survival of mycobacterium tuberculosis or non-tuberculous mycobacteria at the level of macrophages, has the effect of anti-tuberculosis at the level of macrophages, and can be applied to preparation of an inhibitor of mycobacterium tuberculosis or non-tuberculous mycobacteria.The application also discloses that the anti-tuberculosis effect of elvitegravir at the level of macrophages is not the direct action of antibiotics on bacteria, but the inhibition of intracellular survival of tubercle bacillus by targeting and regulating host immune response, so that elvitegravir also has the potential of an immunomodulator, can realize the anti-tuberculosis effect by regulating the immune response of the body to tubercle bacillus infection, and is not affected by drug resistance of mycobacterium tuberculosis, and has a good treatment effect on multidrug-resistant tuberculosis.

The invention discloses a BCG3973 gene knocked-down recombinant bacillus calmette guerin vaccine strain as well as a construction method and application thereof. According to the invention, a CRISPRi / dCas9th1 technology is utilized to block RNA polymerase movement in space through a compound formed by crRNA, dCas9 protein and sgRNA at a transcriptional level, so that the expression of the BCG3973 gene in the BCG vaccine is inhibited. After being treated by the recombinant bacillus calmette guerin bacterial strain, the immune-related pathways of macrophages, such as a cytokine-cytokine receptor action pathway, a Ca < + + > signal pathway and pathways such as PPAR and JAK-STAT, are obviously increased, and IL-1beta, TNF-alpha, antiviral protein and calmodulin with higher levels are expressed, so that the recombinant bacillus calmette guerin bacterial strain has stronger bactericidal ability on escherichia coli. Mouse in-vivo experiments show that the recombinant bacillus calmette-guerin bacterial strain has a very good protection effect on escherichia coli infection and endotoxemia caused by lipopolysaccharide, and shows higher survival rate and stronger capability of eliminating heterologous substance infection under attack of a lethal dose of Candida albicans.

The invention relates to the field of animal nutrition, and discloses application of chicken egg white lysozyme and a drinking water additive. The invention discloses the defect that the iron supplement treatment cannot completely recover the functions of the intestinal panning cells and the proliferation capacity of the epithelium for the first time, and provides the application of the chicken egg white lysozyme in preparation of the preparation for preventing or treating the secondary intestinal infection after iron supplement, and the chicken egg white lysozyme is mixed with edible-grade water-soluble auxiliary materials to prepare the preparation for preventing or treating the secondary intestinal infection after iron supplement. The preparation is prepared in the form of drinking water, wherein the specific activity of the chicken egg white lysozyme is gt; the purity is greater than or equal to 95%; the final concentration of the preparation is controlled to be 10-50 U / mL, and when the preparation is used, 100-500 U of chicken egg white lysozyme can be ingested every day in the iron supplementing period, so that intestinal infection after iron supplementing is prevented or treated, and the intestinal barrier function is recovered. The method is simple and convenient to operate, is suitable for a preventive strategy of large-scale breeding, and can efficiently promote the recovery of intestinal defense and repair functions, so that the intestinal barrier injury caused by subsequent infection of pathogenic bacteria (such as escherichia coli) is remarkably relieved.

This invention discloses the application of oxalic acid in the preparation of drugs against Riemerella anatipestifer infection, belonging to the field of biomedical technology. This invention is the first to discover that oxalic acid can inhibit the growth of Riemerella anatipestifer (RA). After treatment with oxalic acid, the bacterial morphology changes significantly, RA biofilm formation is inhibited, and existing biofilms are destroyed. This indicates that oxalic acid can inhibit related virulence phenotypes, exerting an inhibitory effect on the key steps of RA infection—adhesion and colonization—thereby preventing and controlling RA disease. This invention provides a new potential drug for the development of drugs against Riemerella anatipestifer and lays a theoretical foundation.